Ipilimumab,nivolumab,melanoma,brainmetastases

Mashup Score: 2

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study - 3 day(s) ago

Our findings suggest that ipilimumab plus nivolumab maintains efficacy to at least 7 years in patients with active asymptomatic brain metastasis. Upfront ipilimumab plus nivolumab should be the standard of care for patients with melanoma brain metastasis; a trial investigating the role of stereotactic surgery in this new paradigm is ongoing.

Source: www.thelancet.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- TheLancetOncol
  
  Online First: 7-year follow-up of the ABC study: #Ipilimumab plus #nivolumab versus nivolumab alone in patients with #melanoma #brainmetastases: a multicentre, open-label, randomised, phase 2 study https://t.co/3c9LJXQeFk